Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

Although two-dose mRNA vaccination provides excellent protection against SARS-CoV-2, there is little information about vaccine efficacy against variants of concern (VOC) in individuals above eighty years of age(1). Here we analysed immune responses following vaccination with the BNT162b2 mRNA vaccin...

Descripción completa

Detalles Bibliográficos
Autores principales: Collier, Dami A., Ferreira, Isabella A. T. M., Kotagiri, Prasanti, Datir, Rawlings P., Lim, Eleanor Y., Touizer, Emma, Meng, Bo, Abdullahi, Adam, Elmer, Anne, Kingston, Nathalie, Graves, Barbara, Le Gresley, Emma, Caputo, Daniela, Bergamaschi, Laura, Smith, Kenneth G. C., Bradley, John R., Ceron-Gutierrez, Lourdes, Cortes-Acevedo, Paulina, Barcenas-Morales, Gabriela, Linterman, Michelle A., McCoy, Laura E., Davis, Chris, Thomson, Emma, Lyons, Paul A., McKinney, Eoin, Doffinger, Rainer, Wills, Mark, Gupta, Ravindra K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373615/
https://www.ncbi.nlm.nih.gov/pubmed/34192737
http://dx.doi.org/10.1038/s41586-021-03739-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373615/
https://www.ncbi.nlm.nih.gov/pubmed/34192737
http://dx.doi.org/10.1038/s41586-021-03739-1

Ejemplares similares